Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M115,219Revenue $M51,483Net Margin (%)8.8Z-Score2.7
Enterprise Value $M128,539EPS $5.0Operating Margin %12.2F-Score6
P/E(ttm))25.6Cash Flow Per Share $0Pre-tax Margin (%)11.8Higher ROA y-yY
Price/Book4.710-y EBITDA Growth Rate %6.0Quick Ratio0.9Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %2.7Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %12.5ROA % (ttm)6.7Higher Current Ratio y-yY
Dividend Yield %1.5Insider Buy (3m)0ROE % (ttm)17.6Less Shares Outstanding y-yY
Payout Ratio %35.0Shares Outstanding M827ROI % (ttm)11.0Gross Margin Increase y-yN

Gurus Latest Trades with BAYRY

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAYRYVanguard Health Care Fund 2012-12-31 Reduce-0.21%$83.28 - $96.38
($89.59)
$ 139.2856%Reduce -21.2%2,044,656
BAYRYJohn Keeley 2009-06-30 Sold Out -0.01%$47.66 - $59.35
($52.77)
$ 139.28164%Sold Out0
BAYRYJohn Keeley 2009-03-31 Buy 0.01%$43.75 - $59.4
($52.7)
$ 139.28164%New holding, 6500 sh.6,500
BAYRYJohn Keeley 2008-03-31 Sold Out -0.01%$69.76 - $92.41
($78.8)
$ 139.2877%Sold Out0
BAYRYJohn Keeley 2007-09-30 Buy $68.04 - $79.44
($75.7)
$ 139.2884%New holding, 11000 sh.11,000
BAYRYVanguard Health Care Fund 2007-03-31 Reduce-1.27%$52.14 - $61.01
($56.7)
$ 139.28146%Reduce -22.24%5,944,656
BAYRYVanguard Health Care Fund 2006-09-30 Add1.48%$45.67 - $50.95
($48.9)
$ 139.28185%Add 1811.16%7,644,656
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAYRY is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BAYRY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about BAYRY :

    Quarterly/Annual Reports about BAYRY:

      News about BAYRY:

      Articles On GuruFocus.com
      Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
      Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
      We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
      Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
      Ken Fisher for Forbes - 5 Fantastic Stocks for Fretters Jun 26 2013 
      Pfizer: A Strong Stock for 2013 Apr 20 2012 
      Maxygen Inc. (MAXY): A Magic Formula Stock to Avoid Feb 05 2009 

      More From Other Websites
      Bayer/Regeneron Successfully Expand Eylea Label in Japan Sep 23 2014
      The Zacks Analyst Blog Highlights: Las Vegas Sands, MGM Resorts International, Melco Crown... Sep 22 2014
      Bayer to Shed MaterialScience Business, Shares Rise Sep 19 2014
      Bayer/Orion Progress with Prostate Cancer Drug ODM-201 Sep 18 2014
      Investors Reward Bayer for Adopting a Sharper Focus on Health Care Sep 18 2014
      Bayer to split off polymer division with IPO Sep 18 2014
      Bayer to split off polymer division with IPO Sep 18 2014
      Why Bayer (BAYRY) Stock Is Surging Today Sep 18 2014
      Bayer to Spin Off Plastics Group to Focus on Health Care Sep 18 2014
      Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada Sep 12 2014
      Bayer Presents Positive Long-Term Results on Adempas Sep 09 2014
      OncoMed's Shares Gain on Lifting of Partial Clinical Hold Sep 08 2014
      Bayer/Regeneron Looking for Eylea Label Expansion in Japan Sep 08 2014
      The Zacks Analyst Blog Highlights: Intel, Advanced Micro Devices, Johnson & Johnson, Bayer and... Sep 08 2014
      Bayer Discloses Encouraging Data on Anticoagulant Xarelto Sep 03 2014
      Bayer/Johnson & Johnson to Expand Xarelto Label Further Sep 02 2014
      OncoMed's Vantictumab Studies' Partial Clinical Hold Lifted Aug 29 2014
      Return to Behemoth Stocks Aug 27 2014
      3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology Aug 24 2014
      Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod Aug 22 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK